Use of SGLT2i in Non-Diabetic Kidney Transplant Recipients
Transplantation Proceedings · 2025
DOI: 10.1016/j.transproceed.2024.12.009 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Transplantation Proceedings, 2025. Verfasst von Aina Quilis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Doctor Peset Aleixandre University Hospital, Valencia, Spain. Electronic address: ainaquilis@gmail.com. Hauptthemen laut MEDLINE: Kidney Transplantation, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The potential anti-proteinuric effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) is of special interest in kidney transplantation. Its benefits have been demonstrated in diabetic kidney transplant recipients (KTRs). We analyzed the efficacy and safety of SGLT2i in non-diabetic KTRs collecting clinical and analytical data at baseline and 6 months after the introduction of the drug. METHODS: We performed a unicenter observational study including all non-diabetic KTRs who were prescribed SGLT2i as antiproteinuric therapy. We analyzed clinical and analytical data at baseline and after 6 months of starting SGLT2i. RESULTS: We included 22 patients (68.2% men), median age 58 years, with a median post-transplant period of 67 months. Hypertension was present in 95% of the patients, 90% had dyslipidemia, and 68.2% were receiving treatment with renin-angiotensin-aldosterone system blockade agents plus antialdosterone drugs. The most used SGLT2i was dapagliflozin (91%). The median baseline creatinine was 2.1 (1.48 to 2.85) mg/dL, estimated glomerular filtrate rate (eGFR) 31 (23.7 to 45,2) mL/min, and urinary protein/creatinine ratio 1.68 (0.58 to 2.9) g/g. After 6 months of follow-up, we found a significant reduction in proteinuria (1.68 to 1.06 g/g, P = .025), as well as a reduction in uric acid and high-density lipoprotein (HDL). There was a mild significant reduction in eGFR (31 to 28.5 mL/min, P = .001), which was greater in patients with recurrence of the underlying disease or chronic rejection. The drug was discontinued in two patients (9.1%): one due to a urinary tract infection (UTI) and another one due to hemodialysis initiation. There were no cardiovascular events or death. CONCLUSIONS: The use of SGLT2i in our cohort was effective to reduce proteinuria in non-diabetic KTRs after 6 months of treatment with an acceptable safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Doctor Peset Aleixandre University Hospital, Valencia, Spain. Electronic address: ainaquilis@gmail.com.
- Doctor Peset Aleixandre University Hospital, Valencia, Spain.
- Doctor Peset Aleixandre University Hospital, Valencia, Spain; Fisabio Foundation, Valencia, Spain.
- Doctor Peset Aleixandre University Hospital, Valencia, Spain; Fisabio Foundation, Valencia, Spain; University of Valencia, Valencia, Spain.
Zitieren
APA
Quilis, A., Gavela, E., Kánter, J., Castro-Alonso, C., Calatayud, E., Vivó, E., Parra, M., Gandia, P., & Sancho, A. (2025). Use of SGLT2i in Non-Diabetic Kidney Transplant Recipients. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2024.12.009
Vancouver
Quilis A, Gavela E, Kánter J, Castro-Alonso C, Calatayud E, Vivó E, et al. Use of SGLT2i in Non-Diabetic Kidney Transplant Recipients. Transplantation Proceedings. 2025. doi:10.1016/j.transproceed.2024.12.009
BibTeX
@article{Quilis2025,
author = {Quilis, Aina and Gavela, Eva and Kánter, Julia and Castro-Alonso, Cristina and Calatayud, Emma and Vivó, Elena and Parra, Manuel and Gandia, Paula and Sancho, Asunción},
title = {Use of SGLT2i in Non-Diabetic Kidney Transplant Recipients},
journal = {Transplantation Proceedings},
year = {2025},
doi = {10.1016/j.transproceed.2024.12.009}
}
EUVIMED